Emerson Electric Co. (NYSE: EMR) is a diversified industrial technology and software company, not an ETF. Aggregators report roughly 20 to 30 analysts covering the stock, and the overall average analyst price target clusters near $175 (sources range from about $172 to $181), with a Buy-leaning consensus. Because that mean sits only about 6% above the recent price, it does not represent a meaningful upside threshold on its own.
The $185 central target is therefore calculated differently: it is the rounded average of the individual analyst targets that are above the current share price. Those bullish targets span roughly $170 to $208, with recent actions including J.P. Morgan ($169 to $184), Mizuho ($173 to $180), RBC Capital ($188), Bernstein ($186), Evercore ISI ($190), Wells Fargo's Overweight initiation at $177, UBS ($180), and Citi ($182). More cautious views include Morgan Stanley's Sell at $145 and a Neutral $145 from DA Davidson, while the full published range runs from roughly $104 to $208. The breadth of that range shows genuine disagreement about valuation and the pace of the company's software transition.
EMR last closed near $164.94, close to its 52-week high of roughly $171 after a strong run from the mid-$120s earlier in the year. Reaching $185 implies a rise of about 12%, a substantial but not extreme move for a stock that has already advanced sharply. The path would likely depend on continued execution of Emerson's pivot toward higher-margin automation and industrial software, sustained AI-related demand in process and discrete industries, and margin expansion, all of which would need to offset an elevated valuation around 36x trailing earnings.
EMR has been in a firm uptrend, recently touching a 52-week high near $171 before pulling back about 3% to the mid-$160s. That $170–$171 zone is the nearest resistance level, followed by the $175 area and the $180–$185 analyst-target cluster. On the downside, the recent $160 consolidation zone is an initial support level, with more durable support near $145–$150, which aligns with the cautious analyst targets. A sustained move through $171 would be a necessary first step toward the $185 objective.
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms apply different assumptions. The most immediate catalyst is Emerson's fiscal fourth-quarter earnings report, expected around November 4, 2026, along with guidance for the coming fiscal year. Investors should also monitor analyst target revisions, AI-related order commentary, industrial capital-spending data, and margin trends in the software and automation segments. No single data point will determine whether the target is reached, and no definitive forecast should be assumed.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. This allows traders to screen for emerging opportunities, keep an eye on existing positions, and detect changing trends more efficiently than manual review. Traders seeking a data-driven edge in names like EMR may find these automated signals a useful complement to fundamental research.
The $185 target represents the rounded average of analyst price targets above the current share price, rather than an official published consensus. Reaching it would require a gain of roughly 12% from recent levels near $165. The strongest supports are Emerson's automation and software repositioning, AI-related demand, and improving earnings, while the principal obstacles are a demanding valuation, execution risk in the AspenTech integration, and genuine analyst disagreement that spans from Sell to aggressive Buy ratings. With earnings due in early November, guidance and order commentary will be the most important near-term signals for whether EMR can build toward that objective.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, EMR has been closely correlated with AME. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if EMR jumps, then AME could also see price increases.
| Ticker / NAME | Correlation To EMR | 1D Price Change % | ||
|---|---|---|---|---|
| EMR | 100% | +1.79% | ||
| AME - EMR | 74% Closely correlated | +0.33% | ||
| IR - EMR | 70% Closely correlated | +0.65% | ||
| ROK - EMR | 70% Closely correlated | +1.18% | ||
| LECO - EMR | 69% Closely correlated | -1.15% | ||
| GTES - EMR | 66% Closely correlated | +2.04% | ||
More | ||||
| Ticker / NAME | Correlation To EMR | 1D Price Change % |
|---|---|---|
| EMR | 100% | +1.79% |
| EMR (6 stocks) | 82% Closely correlated | -2.75% |
| Producer Manufacturing (346 stocks) | 14% Poorly correlated | +11.92% |